AstraZeneca and Ionis’ stocks drop significantly on Wainua ATTR-CM trial failure

AstraZeneca and Ionis both saw their stocks take a hit on 9 July following the ATTR-CM trial failure. AstraZeneca and Ionis both saw their stocks take a hit on 9 July following the ATTR-CM trial failure. Both companies saw a significant drop in their stock price at market open on 9 July. Credit: saepul_bahri / Shutterstock.com Both AstraZeneca and Ionis’ stocks took a hit at market open on 9 July after the companies announced that a Phase III trial of Wainua (eplontersen) in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet its primary efficacy endpoint. The CARDIO-TTRansform study (NCT04136171) failed to…

Source: Clinical Trials Arena